Follicular lymphoma is an indolent malignant tumor originating from lymph nodes and lymphoid tissues, which may affect the patients' quality of survival due to the recurrence and progression. In recent years, with the deepening understand of the molecular biology and signaling pathways, many new targeted drugs for follicular lymphoma have been discovered, such as monoclonal antibodies, checkpoint inhibitors, epigenetic regulation related targeted therapies and signaling pathway inhibitors. In this review, the new progress of immunotherapy for follicular lymphoma is summarized briefly.
题目: 滤泡淋巴瘤免疫靶向治疗研究进展.
摘要: 滤泡淋巴瘤是一组起源于淋巴结和淋巴组织等淋巴造血系统的惰性肿瘤，但其复发以及进展的可能性极大影响了患者的生存质量。近年来，随着对分子生物学和信号通路机制的日益深入了解，许多治疗滤泡淋巴瘤的新型靶向药物得以研发，如单克隆抗体、免疫检查点抑制剂、表观遗传调控相关靶向治疗、信号通路抑制剂等。本文就滤泡淋巴瘤免疫靶向治疗的最新研究进展作一综述.
Keywords: antibody drug conjugates; epigenetic therapy; follicular lymphoma; immune check point; molecular inhibitor.